# Plant Monograph: Lungwort
**Name of plant:**
Lungwort
**Catch phrase (Carmina Gadelica or traditional invocation if available):**
No specific invocation to lungwort is recorded in the *Carmina Gadelica*. The traditional name itself is significant: **“Lungwort”**, from the belief that the plant's spotted leaves resembled diseased lung tissue and therefore indicated its usefulness for pulmonary ailments. This is a classic example of the **Doctrine of Signatures**, rather than evidence of an actual anatomical or pharmacological relationship.
**Family:**
Boraginaceae — the borage family
**Genus and species:**
*Pulmonaria officinalis* L.
**Other names:**
Common lungwort; Bethlehem sage; Jerusalem sage; Soldiers and sailors; Mary-spotted lungwort; Spotted dog; Pulmonaria; *Pulmonaria officinalis*.
**Brief introduction:**
Lungwort is a low-growing European perennial herb with rough, oval leaves characteristically marked with pale silvery or whitish spots. Its tubular flowers emerge pink or reddish and gradually become violet-blue as they mature. It is native to parts of central and eastern Europe and is widely cultivated as an ornamental shade plant.
Its spotted leaves gave rise to the traditional belief that it resembled diseased lung tissue, leading European herbalists to employ it for coughs, bronchitis, pulmonary bleeding and other respiratory disorders. The plant consequently became one of the classic examples of the Doctrine of Signatures.
Modern phytochemical research has identified a considerable variety of phenolic compounds in *P. officinalis*, including caffeic-acid derivatives, rosmarinic-acid-related compounds and other polyphenols. Research has also investigated antioxidant, antimicrobial and anti-inflammatory properties, but **clinical evidence supporting lungwort as a treatment for pulmonary disease remains limited**. ([PubMed Central (PMC)][1])
**Traditional uses:**
* Used traditionally for coughs and irritation of the respiratory tract.
* Employed for bronchitis and other inflammatory respiratory complaints.
* Used historically as an expectorant to assist the removal of mucus.
* Traditionally employed for sore throat and hoarseness.
* Used as an astringent for minor bleeding and inflammatory conditions.
**Historical use:**
* Medieval and Renaissance European herbalists associated the spotted leaves with diseased lungs.
* Lungwort was consequently prescribed for cough, bronchitis and other pulmonary complaints.
* It was traditionally prepared as an infusion or decoction of the aerial herb.
* European folk medicine also employed the plant for throat and urinary complaints.
* The plant was sometimes incorporated into “lung” formulations containing several other respiratory herbs.
**Parts used and method of use:**
* Leaves and flowering aerial parts.
* Occasionally the whole above-ground herb.
Used as:
* Infusion or herbal tea.
* Decoction.
* Fresh herb or expressed juice in historical practice.
* Syrup or compound respiratory preparation.
**Use in healing (modern herbal practice):**
* Traditionally used as a soothing respiratory herb for coughs.
* Used historically as an expectorant and demulcent.
* Traditionally employed for bronchial irritation.
* Used as an astringent herb for minor mucosal irritation.
* Investigated experimentally for antioxidant, antimicrobial and anti-inflammatory activity.
Modern evidence is insufficient to establish lungwort as a treatment for asthma, pneumonia, tuberculosis, chronic bronchitis or other serious pulmonary disease. The traditional respiratory applications are well documented ethnobotanically, but the clinical evidence remains comparatively weak. ([PubMed Central (PMC)][1])
**Pharmacology and biochemistry:**
* **Rosmarinic acid and related caffeic-acid derivatives**.
* **Phenolic acids and polyphenols**, including complex caffeic-acid conjugates.
* **Flavonoids, tannins and other secondary metabolites**.
Mechanisms:
* Polyphenolic constituents demonstrate **antioxidant activity** in experimental systems.
* Rosmarinic-acid derivatives may influence inflammatory signalling and oxidative stress pathways.
* Phenolic and other constituents have demonstrated antimicrobial activity in laboratory studies, although this cannot be directly equated with clinical efficacy.
**Overall profile:**
Lungwort is primarily a **traditional European respiratory herb whose pharmacological chemistry is more interesting than its clinical evidence is strong**. Its historical reputation arose largely through the Doctrine of Signatures. Modern research confirms that it contains substantial phenolic chemistry with antioxidant and other biological activities, but it does not establish that the plant specifically “heals the lungs.” ([PubMed Central (PMC)][1])
**Common dosage:**
* **Infusion:** Approximately 2–5 g dried aerial herb per cup of hot water, traditionally taken as needed; no standardized clinical dosage has been established.
* **Decoction:** Approximately 2–5 g dried herb prepared as a decoction; traditional rather than clinically validated.
* **Tincture:** Preparation-specific dosing should be followed because concentrations vary considerably.
* **Syrup:** Historically incorporated into compound cough syrups; no standardized modern therapeutic dose exists.
Because the evidence base is limited and commercial preparations vary, these quantities should be regarded as **traditional herbal ranges rather than evidence-based treatment doses**.
**Safety factors (including side effects):**
* The chemistry and safety profile of *Pulmonaria officinalis* are not as well characterized clinically as those of established medicinal herbs.
* Some members of the Boraginaceae family contain **pyrrolizidine alkaloids (PAs)**, which can be hepatotoxic and, for certain compounds, carcinogenic. ([European Medicines Agency (EMA)][2])
* Species authentication and sourcing from reputable suppliers are therefore particularly important for internal preparations.
* Pregnancy and breastfeeding should be considered contraindications to medicinal internal use because adequate safety information is lacking.
* Long-term internal use should be avoided unless the preparation has been appropriately tested for toxic pyrrolizidine alkaloids.
**First aid / adverse reaction response:**
* **Mild gastrointestinal upset:** Discontinue use and monitor; seek medical advice if symptoms persist.
* **Skin irritation or allergic reaction:** Stop exposure and wash affected skin if the reaction followed topical contact.
* **Suspected significant ingestion of an incorrectly identified Boraginaceae herb:** Contact a poison-control centre or medical professional promptly.
* **Jaundice, severe abdominal pain, unusual fatigue or other signs potentially consistent with liver injury:** Stop use and seek urgent medical evaluation.
**Drug interactions:**
* **Hepatotoxic medications:** Theoretical concern exists if a preparation contains toxic pyrrolizidine alkaloids.
* **Anticoagulant or antiplatelet medicines:** Traditional astringent and polyphenolic effects do not establish a clinically meaningful interaction, but evidence is insufficient.
* **Liver-metabolized medications:** Potential interaction is uncertain because the pharmacokinetics of medicinal lungwort preparations have not been adequately established.
* **General interaction considerations:** Avoid medicinal internal use of poorly characterized products, particularly products lacking testing for pyrrolizidine alkaloids.
**Horticultural requirements:**
* USDA / Canadian zone: **USDA Zones 4–8**.
* Soil pH: **Approximately 6.0–7.5**.
* Light requirements: **Partial shade / shade**.
* Moisture: **Moderately moist, humus-rich soil; avoid prolonged drought**.
* Other notes (growth habit, harvest timing, etc.):
* **Growth habit:** Low-growing rhizomatous perennial, generally 15–30 cm tall, forming spreading clumps.
* **Flowering/fruiting:** Flowers appear early in spring, changing from pink or reddish tones to violet-blue as they mature.
* **Harvest timing:** Aerial parts are traditionally collected during flowering in spring.
* **Habitat:** Woodland margins, deciduous forests, shaded banks and other cool, humus-rich habitats.
* **Propagation/cultivation notes:** Propagated by division or seed. It prefers cool, shaded conditions and moisture-retentive soil rich in organic matter. It makes an excellent woodland or shade-garden plant.
**Sampling of clinical reports / studies:**
* **Clinical study or report:** Modern clinical evidence specifically evaluating *Pulmonaria officinalis* for respiratory disease is sparse; no strong clinical evidence establishes it as an effective treatment for major pulmonary disorders.
* **Pharmacological study:** Experimental research has investigated antioxidant, antimicrobial and anti-inflammatory properties associated with the plant's phenolic constituents. ([PubMed Central (PMC)][1])
* **Phytochemical study:** LC-MS/MS and NMR investigations identified numerous phenolic constituents, including caffeic-acid esters, rosmarinic-acid derivatives, lignans and previously undescribed phenolic compounds. ([PubMed Central (PMC)][1])
* **Ethnobotanical evidence:** Lungwort has a long European history as a remedy for coughs, bronchitis, asthma and other respiratory complaints. ([PubMed Central (PMC)][1])
* **Overall assessment of evidence:** **Strong historical evidence for respiratory use; substantial modern phytochemical interest; preliminary pharmacological evidence; insufficient clinical evidence for therapeutic claims.**
**A particularly important note for the collection:**
Lungwort is an excellent plant for demonstrating how the **Doctrine of Signatures shaped European materia medica**. Its spotted leaves genuinely do look remarkably like illustrations of diseased lung tissue, and that visual resemblance appears to have reinforced its traditional respiratory reputation. But the historical logic should not be confused with pharmacological proof.
There is also a naming trap worth preserving in the monograph. **“Lungwort” is not botanically unique.** The name has also been applied to the lichen *Lobaria pulmonaria*, sometimes called lungwort lichen, because its lobed surface was likewise thought to resemble lung tissue. That lichen is a completely different organism. For this monograph, the medicinal plant is specifically *Pulmonaria officinalis*.
And there is one modern safety issue that deserves particular emphasis: **Boraginaceae plants and pyrrolizidine alkaloids**. The presence and concentration of these compounds can vary considerably between species and preparations, and several unsaturated PAs are recognized as hepatotoxic. The EMA specifically identifies the hepatotoxic and carcinogenic potential of certain PAs and provides guidance for controlling them in herbal medicines. ([European Medicines Agency (EMA)][2])
For the apothecary, I would therefore classify *Pulmonaria officinalis* as a **traditional European respiratory herb with significant historical value and interesting phytochemistry, but requiring careful botanical authentication and PA-conscious sourcing**.
[1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6225171/?utm_source=chatgpt.com "Novel Phenolic Constituents of Pulmonaria officinalis L. LC-MS/MS Comparison of Spring and Autumn Metabolite Profiles - PMC"
[2]: https://www.ema.europa.eu/en/use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-scientific-guideline?utm_source=chatgpt.com "Use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) - Scientific guideline | European Medicines Agency (EMA)"
Educational Use Only: The information presented on this page is provided for educational, historical, and informational purposes only. ArdNemeton na Tuatha and Bhùth Draoi do not provide medical advice. Always consult your physician and pharmacist before using any herb, mushroom, supplement, or botanical product for medicinal purposes. Traditional uses described herein do not constitute medical claims.